LSX MART |
Code |
|
Stage |
Ask
|
Last Bid
|
Change |
Date |
Bids’ Average |
Make a Bid |
Select * from transaction_buy_sell where ip_id='1' limit 0, 20 |
00020 | HIV-1 TAT, or derivatives thereof for prophylactic and therapeutic vaccination |
Phase I |
187,500,000.00 |
0.00 |
|
|
25,540,625.00 |
|
| |
00051 | Treatment and prevention of B12 deficiency in elderly |
NDA |
|
0.00 |
|
|
|
|
| |
00021 | AIDS, Novel antigen formed by specific molecular complex between ENV and TAT |
Phase I |
151,875,000.00 |
562,500.00 |
0.00% |
01Dec2007 |
562,500.00 |
|
| |
00022 | AIDS, Microparticles for delivery of protein antigens and therapeutics |
Pre-clinical |
750,000.00 |
|
|
|
|
|
| |
00023 | Recombinant Herpes Simplex Virus Vector |
Pre-clinical |
25,000.00 |
234,375.00 |
0.00% |
12Mar2008 |
234,375.00 |
|
| |
00024 | HIV-1 Tat to target and/or activate antigen- presenting cells, and/or to deliver cargo molecules |
Phase I |
19,800,000.00 |
750,000.00 |
0.00% |
28July2008 |
750,000.00 |
|
| |
00025 | AIDS, Vaccines containing the HIV TAT protein as an adjuvant for the enhancement of cytotoxic T- cel |
Phase I |
5,625,000.00 |
|
|
|
|
|
| |
00026 | AIDS,Biocompatible polymeric nano-microparticles as a potential carrier for DNA. |
Pre-clinical |
281,250.00 |
|
|
|
|
|
| |
00027 | Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell f |
Phase II |
281,250.00 |
|
|
|
|
|
| |
00028 | Novel, diagnostic antigen for colorectal cancer, uses thereof, and especially the use thereof in imm |
Pre-clinical |
750,000.00 |
|
|
|
|
|
| |
00029 | Compositions and methods for use in affecting hematopoietic stem cell populations in mammals. |
Pre-clinical |
37,500.00 |
|
|
|
|
|
| |
00030 | In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic pa |
Pre-clinical |
37,500.00 |
93.75 |
-26,999,900.00% |
29Nov2007 |
12,656,296.88 |
|
| |
00031 | Inhibition of Endogenous RT Antagonizes Human Tumor Growth |
Discovery |
37,500.00 |
117,187.50 |
0.00% |
24June2007 |
117,187.50 |
|
| |
00032 | Method of inactivating prions |
Phase II |
|
|
|
|
|
|
| |
00033 | MicroRNA therapy for kit-dependent tumors |
Pre-clinical |
|
1,406,250.00 |
-98.00% |
03Mar2008 |
2,095,312.50 |
|
| |
00034 | NNRTI as antagonists of cell proliferation and inducers of cell differentiation. |
Phase I |
|
|
|
|
|
|
| |
00035 | Novel Analgesic product for inflammatory pain |
Pre-clinical |
|
|
|
|
|
|
| |
00043 | Novel endothelial antigen for Behçet disease (BD) |
Pre-clinical |
|
|
|
|
|
|
| |
00037 | Novel library of synthetic NGF agonists that bind in a highly specific manner the tropomyosin kinase |
Pre-clinical |
|
|
|
|
|
|
| |
00038 | Treatment of cognitive and learning impairment through the use of a bacterial toxins called CNF1 . |
Pre-clinical |
|
|
|
|
|
|
| |
| 1 2 [Next] [Last Page] |
